2021 Fiscal Year Annual Research Report
Stapled peptide-based radiotheranostics for intracellular protein-protein interactions targeted cancer imaging and therapy
| Project/Area Number |
21H02873
|
|---|
| Research Institution | National Institutes for Quantum Science and Technology |
|---|
Principal Investigator |
胡 寛 国立研究開発法人量子科学技術研究開発機構, 量子医科学研究所 先進核医学基盤研究部, 研究員 (00827678)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
謝 琳 国立研究開発法人量子科学技術研究開発機構, 量子医科学研究所 先進核医学基盤研究部, 主任研究員 (30623558)
破入 正行 国立研究開発法人量子科学技術研究開発機構, 量子医科学研究所 先進核医学基盤研究部, 主任研究員 (80435552)
張 明栄 国立研究開発法人量子科学技術研究開発機構, 量子医科学研究所 先進核医学基盤研究部, 部長 (80443076)
|
|---|
| Project Period (FY) |
2021-04-01 – 2025-03-31
|
| Keywords | stapled peptide / radiotheranostics / intracellular protein / cancer / 64Cu |
|---|
| Outline of Annual Research Achievements |
This research project aims at the development of stapled peptide-based radiotheranostics for targeting intracellular protein protein interactions. In the past fiscal year, I developed a stapled peptide based, 64Cu labeled radiotheranostics, which can specifically bind to hDM2 in various cancer cells. The radiotheranostics, [64Cu]STP08, showed high tumor accumulation and retention in several animal models.More importantly, it significantly delayed tumor growth in mouse models and the efficacy is independent to the p53 phenotype.Biosafety study suggested that [64Cu]STP08 showed satisfactory and caused no hemotological and organ lesions in normal mice.
Moreover, we have successfully labelled STP with 225Ac, an alpha particle emitting radionuclide. The [225Ac]STP08 showed excellent treatment efficacy.
|
| Research Progress Status |
翌年度、交付申請を辞退するため、記入しない。
|
| Strategy for Future Research Activity |
翌年度、交付申請を辞退するため、記入しない。
|
Research Products
(13 results)
